01
Why people want it
Nootropic marketing is loud. The molecule has a real research story. We will not oversell either.
- ·Cognitive research interest
- ·Not a study-drug promise
- ·Not orderable today
RE GEN RX · peptides / Semax
Under FDA review
Semax
A nootropic peptide PCAC recommended for the 503A bulks list — not orderable yet.
Oswego, Illinois · 74 W. Washington St · serving the Fox Valley. A licensed Illinois clinician still decides. Compounded medications are not FDA-approved.
Legal status reviewed July 2026 · Cycle discussed at consult
What is Semax?
The molecule, in plain language.
Semax is a ACTH(4-10) analog studied for cognitive and neuroprotective research. In July 2026, FDA’s Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list. A recommendation is advice to FDA. It is not listing, not rulemaking, and not a vial we can send.
How people usually take it. Not orderable today. No RE GEN Semax nasal or injectable.
What people are actually trying to solve.
Interest is not a result. We keep the research language and skip the miracle.
02
What the July 2026 vote actually did
PCAC recommended six peptides, including Semax. Emideltide (DSIP) was not recommended. None of the six became compoundable the next morning.
- ·Advisory only
- ·Rulemaking still required
- ·See the peptides hub legal grid
03
If FDA lists it later
If FDA places Semax on the 503A bulks list and the other gates are clear, we will add it with its basis — not before.
- ·We will update this page
- ·No gray-market bridge
- ·Ask us what is carried now
What the evidence actually is — and what it isn’t.
A note on honesty: we will tell you what the literature supports and what it does not. Animal data is not a human guarantee. Anecdotes are not trials.
Animal research
Semax has a preclinical neurobiology literature.
- ·Cognitive and stress models
- ·Not a U.S. approval
- ·Not orderable
Human research
Human studies exist, especially outside U.S. commercial channels. PCAC review is not the same as FDA listing.
- ·Limited as a U.S. compounding basis today
- ·No promised cognitive result
- ·Do not buy research Semax
Legal basis at RE GEN · July 2026
We will not compound this today.
PCAC recommended Semax for the 503A bulks list in July 2026. That is not a green light. Not orderable at RE GEN until FDA acts and a lawful basis is confirmed.
PCAC recommended listing is not a green light. Not orderable today.
Common questions
Peptide education for Illinois patients at RE GEN in Oswego — not a substitute for a visit.
What is Semax?
A peptide studied in cognitive and neuroprotective research. PCAC recommended it for the 503A bulks list in July 2026. Not orderable yet.
Is Semax FDA-approved?
Semax is not FDA-approved, and RE GEN does not have a lawful §503A pathway to request it as a compounded medication today. A committee vote is not approval.
Can I get Semax at RE GEN in Oswego?
You can start a visit to talk about your goal. We will not compound Semax today. We will show you what is carried instead — and we will say no rather than gray-market a vial.
Didn’t the committee approve it?
Committees recommend. FDA lists — after rulemaking. A vote is not a vial.
Do you promise results?
No. Educational pages explain why people ask and what the research landscape looks like. Individual response varies. Compounded medications are not FDA-approved, and a request is not a guaranteed prescription.
Related on this menu
Illinois practice · licensed 503A compounding
A committee vote is not a green light. We add a peptide when FDA does.
Hello Gorgeous PC · 74 W. Washington St, Oswego, IL
RE GEN desk 630-636-6193
Start a visit, a licensed Illinois clinician reviews, then you pay the invoice. If they don't prescribe, we refund.